Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

Journal of Diabetes Investigation

Volumn 9, Issue 6, 2018, Pages 1323-1332

  Matsuba, Ikuro ^a   Matsuba, Ren ^b   Ishibashi, Shun ^c   Yamashita, Shizuya ^d,e   Arai, Hidenori ^f   Yokote, Koutaro ^g   Suganami, Hideki ^h   Araki, Eiichi ⁱ  

^a Matsuba Clinic   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Rinku General Medical Center   (Japan)

^f NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^g CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h KOWA COMPANY LTD   (Japan)

ⁱ KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Glucose clamp(s); Insulin resistance; Selective peroxisome proliferator activated receptor modulator

Indexed keywords

CREATINE KINASE; FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN; PEMAFIBRATE; PLACEBO; TRIACYLGLYCEROL; DURAGEL 75; METHACRYLIC ACID METHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; POVIDONE;

ADULT; ARTHROPOD DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; HYPERTRIGLYCERIDEMIA; INSECT STING; INSULIN RESISTANCE; INSULIN SENSITIVITY; JAPAN; LIVER FUNCTION TEST; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; URTICARIA; AGONISTS; CLINICAL TRIAL; COMPLICATION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; LIVER; LIVER CIRCULATION; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER; LIVER CIRCULATION; MALE; METHYLMETHACRYLATES; MIDDLE AGED; POVIDONE; PPAR ALPHA; TREATMENT OUTCOME;

EID: 85046038740     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12845     Document Type: Article

References (44)

1. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340: 925–929
2. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 1270–1287
3. Robins SJ, Lyass A, Zachariah JP, et al. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2011; 31: 1208–1214
4. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649–688
5. Bajaj M, Suraamornkul S, Hardies LJ, et al. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007; 50: 1723–1731
6. Kawamori R, Matsuhisa M, Kinoshita J, et al. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract 1998; 41: 35–43
7. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710–719
8. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–514
9. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169–2176
10. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013; 36: 2923–2930
11. Lee CH, Olson P, Hevener A, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006; 103: 3444–3449
12. Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003; 100: 15924–15929
13. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088–2093
14. Black RN, Ennis CN, Young IS, et al. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial. J Diabetes Complications 2014; 28: 323–327
15. Shiochi H, Ohkura T, Fujioka Y, et al. Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study. Diabetol Metab Syndr 2014; 6: 113
16. Taniguchi A, Fukushima M, Sakai M, et al. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 2001; 50: 477–480
17. Fruchart JC. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol 2013; 12: 82
18. Raza-Iqbal S, Tanaka T, Anai M, et al. Transcriptome Analysis of K-877 (a Novel Selective PPARalpha Modulator (SPPARMalpha))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver. J Atheroscler Thromb 2015; 22: 754–772
19. Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis 2016; 249: 36–43
20. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281–344
21. Araki E, Ishibashi S, Yamashita S, et al. A highly potent and specific PPAR alpha agonist, K-877, improves lipid profiles and insulin sensitivity in dyslipidaemia subjects; an integrated analysis of 3 Phase 2/3 trials. ePoster #663 presented at EASD 2014 2014 [cited 2016 14 December]. Available from: http://www.easdvirtualmeeting.org/resources/a-highly-potent-and-specific-ppar-alpha-agonist-k-877-improves-lipid-profiles-and-insulin-sensitivity-in-dyslipidaemiasubjects-an-integrated-analysis-of-3-phase-2-3-trials-2
22. Tripathy D, Almgren P, Tuomi T, et al. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004; 27: 2204–2210
23. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 2016; 8: 101–109
24. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3–10
25. Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 2010; 91: 254s–257s
26. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–E223
27. Pilo AFE, Björkman O, Wahren J, et al. Analysis of glucose production and disappearance rates following an oral glucose load in normal subjects: a double tracer approach. In: Cobelli CBR (ed). Carbohydrate Metabolism: Quantitative Physiology and Mathematical Modelling. London: John Wiley & Sons, Ltd., 1981; 221–228
28. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364–1370
29. Kawamori R, Morishima T, Ikeda M, et al. Effect of strict metabolic control on glucose handling by the liver and peripheral tissues in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1994; 23: 155–161
30. Ludvik B, Nolan JJ, Roberts A, et al. A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. J Clin Invest 1995; 95: 2232–2238
31. Sato F, Tamura Y, Watada H, et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007; 92: 3326–3329
32. Basu R, Basu A, Johnson CM, et al. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes 2004; 53: 2042–2050
33. Tamura Y, Tanaka Y, Sato F, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005; 90: 3191–3196
34. Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol 2012; 11: 140
35. Inokuchi Y, Goto S, Takizawa T, et al., editors. K-877, a highly potent and selective PPARa modulator, increases plasma FGF21 and improves triglyceride metabolisms in Zucker fatty rats. ISA 2015; 2015; Amsterdam
36. Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 2017; 261: 144–152
37. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844–1850
38. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–455
39. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26: 856–863
40. Tomita T, Yamasaki Y, Kubota M, et al. High plasma free fatty acids decrease splanchnic glucose uptake in patients with non-insulin-dependent diabetes mellitus. Endocr J 1998; 45: 165–173
41. Ferrannini E, Barrett EJ, Bevilacqua S, et al. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72: 1737–1747
42. Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8: 169–174
43. Berglund ED, Li CY, Bina HA, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009; 150: 4084–4093
44. Haluzik MM, Lacinova Z, Dolinkova M, et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 2006; 147: 4517–4524